5.50
+0.18(+3.38%)
Currency In USD
| Previous Close | 5.32 |
| Open | 5.32 |
| Day High | 5.54 |
| Day Low | 5.24 |
| 52-Week High | 12.36 |
| 52-Week Low | 3.79 |
| Volume | 12.52M |
| Average Volume | 25.71M |
| Market Cap | 2.17B |
| PE | -3.14 |
| EPS | -1.75 |
| Moving Average 50 Days | 6.73 |
| Moving Average 200 Days | 6.92 |
| Change | 0.18 |
If you invested $1000 in Recursion Pharmaceuticals, Inc. (RXRX) since IPO date, it would be worth $175.72 as of April 18, 2025 at a share price of $5.5. Whereas If you bought $1000 worth of Recursion Pharmaceuticals, Inc. (RXRX) shares 3 years ago, it would be worth $842.27 as of April 18, 2025 at a share price of $5.5.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries
GlobeNewswire Inc.
Apr 09, 2025 12:00 PM GMT
Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced the generation of screening libraries leveragin
Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
GlobeNewswire Inc.
Apr 08, 2025 12:00 PM GMT
REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitorsSalt Lake City, UT, April 08, 2025 (GLOBE NEWSWIRE) -- Recur
Recursion to Participate in Upcoming Investor Conference
GlobeNewswire Inc.
Apr 01, 2025 12:00 PM GMT
Salt Lake City, UT, April 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today its participation in the following upcoming investor confere
Data not available